Systemic Sclerosis-Associated Interstitial Lung Disease: Making Connections, Elevating Care

To participate in this activity, please:

Renowned pulmonologist, Imre Noth, MD, and scleroderma expert rheumatologist, Elizabeth Volkmann, MD, MS, discuss the importance of screening patients with systemic sclerosis (SSc) to identify those at risk for interstitial lung disease (ILD) even before respiratory symptoms are reported. Risk factors, burden of disease, and comorbidities associated with SSc-ILD are presented. This rare multisystemic disease affects the lungs, heart, and kidneys, in addition to the skin and gastrointestinal tract. Careful monitoring and ongoing evaluation are required to minimize lung complications. The latest first-line treatments and combination strategies are reviewed, along with data of FDA-approved targeted therapies as the faculty provide insights to individualize treatment so as to improve patient outcomes. Faculty case presentations describe treatment strategies and address how best to optimize clinician-patient communication in this innovative education format.

Editor’s Note: The faculty for this enduring activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.

Course Credit:

2.00 AMA PRA Category 1 CreditsTM


Opens: 2022-02-28
Closes: 2023-02-28

Target Audience:

This activity was developed for pulmonologists, radiologists, rheumatologists, dermatologists, and primary care physicians, as well as other clinicians who care for patients with interstitial lung disease.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Victoria Anderson (Medical Writer)

Individual stockholder: Abbott, AbbVie

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Imre Noth, MD

    Professor of Medicine
    Chief, Division of Pulmonary and Critical Care
    University of Virginia
    Charlottesville, Virginia

  • Elizabeth Volkmann, MD

    Associate Professor
    Director, UCLA Scleroderma Program
    Co-Director, CTD-ILD Program
    Division of Rheumatology
    Department of Medicine
    University of California
    Los Angeles, California

Learning Objectives

  • Recognize the healthcare and economic burden associated with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) and the need to evaluate, monitor, and manage lung involvement in patients with SSc
  • Identify patients with SSc to screen for ILD
  • Select appropriate treatment for patients with SSc-ILD
  • Identify the risk factors for SSc-ILD and its associated comorbidities, and recognize the need to manage comorbidities in patients with SSc-ILD
  • Apply strategies for optimal clinician-patient communication and for education of patients with SSc-ILD

Faculty Disclosures

Imre Noth, MD

Advisory Board: Boehringer Ingelheim, Genentech

Contractor: Genentech       

Consultant: Boehringer Ingelheim, Parion Sciences, Sanofi

Elizabeth Volkmann, MD

Consultant: Boehringer Ingelheim

Research Support: Corbus, Forbius, Kadmon

Speakers Bureau: Boehringer Ingelheim